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Abstract 
Background: A post-marketing surveillance study has reported an association between meropenem use and the 
incidence of hematologic abnormalities, including leukopenia, thrombocytopenia, hemolysis, and neutropenia, but 
the precise incidence in neonates is unknown. Here, we report meropenem-induced pancytopenia in a preterm 
neonate.
Case presentation: A preterm newborn Pakistani received intravenous meropenem 40 mg/kg every 8 hours to treat 
Klebsiella pneumoniae in blood cultures and suspected meningitis. The baby developed severe thrombocytopenia, 
with a platelet count of 22 × 103 cells/mm3, low hemoglobin level of 9.7 g/dl, and low absolute neutrophil count 
(ANC) of 816 cells/mm3 on days 3, 14, and 17 of meropenem therapy, respectively. Based on the blood culture and 
institutional guidelines, meropenem treatment was continued with monitoring and supportive care for a total of 19 
days. After discontinuation of meropenem, the baby was monitored continuously for hematological changes, and 
low counts persisted for 3 days. ANC improved to > 1500 cells/mm3 on the fourth day, and the platelet count reached 
> 150 × 103 cells/mm3 for the first time on the seventh day of meropenem discontinuation. All subsequent com-
plete blood count (CBC) reports showed improving trends. The baby was discharged on the 48th day of life (DOL), 
with follow-up monitoring of CBC. The baby was kept on iron supplements, and hemoglobin level of 11.2 g/dl was  
observed on the 59th DOL.
Conclusion: Neonatal pancytopenia may lead to serious health complications; therefore, clinicians and pharmacists 
need to vigilantly monitor CBC in this vulnerable population, even when administering meropenem in septic doses 
for the recommended duration.
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Background
Pancytopenia is defined as reduced white blood cell 
(WBC) count, hemoglobin, and platelet count. Pan-
cytopenia occurs when hemoglobin is <  13  g/dl in 
males and <  12  g/dl in females, absolute neutrophil 
count (ANC) is < 1500 cells/mm3, and platelet count is 
< 150 × 103 cells/mm3 [1]. Pancytopenia is considered 
severe if a patient experiences two or more of the fol-
lowing: hemoglobin <  7  g/dl, ANC  <  500 cells/mm3, 
and platelet count <  50 ×  103  cells/mm3. The mecha-
nism underlying pancytopenia mainly involves bone 
marrow infiltration, bone marrow aplasia, and blood 
cell destruction that results in peripheral blood leak-
age [1]. Suppression of bone marrow varies widely in 
the pediatric population but may occur due to toxins, 
infection, or malignant cell infiltrates that can lead to 
hypocellular bone marrow function. Drug-induced 
pancytopenia is also a rare but secondary cause of 
bone marrow suppression due to direct bone marrow 
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toxicity, immune-mediated (complement or antibody-
mediated) cell destruction, and hapten formation, and 
directly affects myeloid precursors [2, 3]. An in vitro 
study of several beta-lactam antibiotics established the 
presence of well-differentiated myeloid cells and copi-
ous granulocyte precursors along with dose-dependent 
suppression of granulopoiesis [4]. Antibody-mediated 
hemolytic anemia and thrombocytopenia have also 
been established in meropenem-treated patients [5, 6]. 
Several medications can cause pancytopenia includ-
ing chemotherapeutics, antiepileptics, antidepressants, 
and antibiotics [3, 5, 7]. A case–control epidemiologi-
cal surveillance study was conducted over a follow-up 
period of 78.7  million person-years to assess the inci-
dence of drug-induced agranulocytosis. Around 396 
confirmed cases of acute neutropenia were observed, 
with an overall incidence of 3.5:1  million per year [8]. 
It was found that agranulocytosis clearly increased the 
risk of mortality, with a fatality rate of 9.1%. The most 
common drugs causing agranulocytosis were dipy-
rone (16%), beta-lactam antibiotics (12.0 %), ticlopi-
dine (11.1%), antithyroid drugs (7.2%), and sulfonamide 
antibiotics (5.4%) [8].
Meropenem is one of the beta-lactam antibiotics that 
can cause serious and life-threatening neutropenia. It 
is a bactericidal broad-spectrum antibiotic with gram-
positive, gram-negative, and anaerobic coverage, and is 
mainly used in the treatment of severe gram-negative 
infections in neonates including severe sepsis, menin-
gitis, and complicated intra-abdominal infections such 
as necrotizing enterocolitis (NEC), one of the most 
common gastrointestinal emergencies and a major 
cause of morbidity and mortality in preterm neonates. 
For improved clinical outcomes, early recognition and 
aggressive management with broad-spectrum or com-
bination antimicrobial agents is most often undertaken 
to treat NEC [9]. Because of its broad-spectrum activ-
ity, meropenem is an agent of great utility [10]. Based 
on the increasing trends of morbidity and mortality due 
to multidrug-resistant gram-negative bacterial infec-
tions in our neonatal intensive care unit (NICU), and 
following institutional guidelines, other antibiotics 
such as vancomycin and colistin are also used [11–13] 
after infectious disease (ID) consultation. The most 
common adverse effects of meropenem are constipa-
tion or diarrhea, nausea, vomiting, rashes, and diaper-
area moniliasis in pediatric patients [14]. Some cases of 
meropenem-induced neutropenia have been reported 
[15]. However, no known case of meropenem-induced 
pancytopenia in neonates has yet been published. Here 
we report an event of meropenem-induced pancyto-
penia in a neonate admitted to the NICU of a tertiary-
care hospital.
Case presentation
A newborn Pakistani baby was transferred to the inten-
sive care unit due to prematurity, low birth weight, and 
intrauterine growth retardation. Her birth weight was 
0.71 kg and APGAR scores were 3 at 1 minute and 4 at 
5 minutes. Delivered by emergency C-section at 29 weeks 
due to raised blood pressure and fetal distress, she was 
initially kept on continuous positive airway pressure 
(CPAP) and given nothing through the mouth, and total 
parenteral nutrition (TPN) was started. Caffeine was 
loaded at 20 mg/kg and continued as the standard of care 
for apnea of prematurity. A prophylactic dose of 1 mg of 
vitamin K was given. During the first 24 hours, complete 
blood count (CBC) results were WBC of 18.3 × 103 cells/
mm3, ANC of 1244 cells/mm3, platelet count of 166 × 103 
cells/mm3, and hemoglobin of 17.8  g/dl. On the second 
day of life (DOL), ampicillin and gentamicin were started 
as empirical therapy, and the CBC report showed WBC 
4 × 103 cells/mm3, ANC of 760 cells/mm3, platelet count 
of 152 × 103 cells/mm3, and hemoglobin of 15.9 g/dl. In 
addition, fluconazole was started as antifungal prophy-
laxis. The patient was given phototherapy. Chest X-ray 
and ultrasound of the head were performed, with normal 
findings. CPAP was tapered to high flow on merit, and 
blood culture was sent.
On the fourth DOL, the baby developed issues of severe 
respiratory distress and abdominal distension along with 
metabolic acidosis. She was intubated and kept on syn-
chronized intermittent mandatory ventilation (SIMV) 
mode. The CBC results showed ANC of 912 cells/mm3, 
platelet count of 99 × 103 cells/mm3, and hemoglobin of 
12.7 g/dl. Inotropic support was started, and antibiotics 
were escalated to meropenem 20 mg/kg every 12 hours, 
vancomycin 10 mg/kg once daily, and colistin at a loading 
dose of 5  mg/kg with a maintenance dose of 1.5  mg/kg 
every 12 hours. Blood culture showed no growth. After 
ID consult, vancomycin was discontinued on the third 
day and a decision was made to continue meropenem 
and colistin [11–13] to manage NEC and sepsis.
On the fifth DOL, echocardiogram was performed and 
showed patent ductus arteriosus (PDA) of 3  mm with 
severe persistent pulmonary hypertension of the new-
born (PPHN). Acetaminophen was started for the next 5 
days. On the sixth day of meropenem therapy, the plate-
let count dropped to 42 × 103 cells/mm3, treated in line 
with sepsis-associated thrombocytopenia [16], and man-
aged by transfusion of 10 ml/kg platelet units [17]. Mero-
penem and colistin were discontinued on the eighth day 
of therapy, and trophic feeding was started. An echocar-
diogram was repeated on day 11, which showed a closed 
PDA and moderate PPHN. On the 18th DOL, the child 
was successfully extubated and kept on high-flow oxygen. 
There was slow progress in feeding.
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On the 22nd DOL, the baby had tachycardia and an 
episode of 99.7 °F fever. Thus, septic workup was done 
and showed WBC count of 17.4 × 103 cells/mm3, ANC of 
12,632.4 cells/mm3, and platelets of 203 × 103 cells/mm3. 
C-reactive protein (CRP) was 77 mg/l and renal function 
was normal (blood urea nitrogen [BUN] of 11 mg/dl and 
creatinine of 0.2 mg/dl). Meropenem was started in men-
ingitic doses of 40 mg/kg every 8 hours [10] along with 
vancomycin 15 mg/kg every 12 hours.
In the microbiological investigation, urine and cerebro-
spinal fluid (CSF) cultures were found to be negative, but 
the blood culture was positive for Staphylococcus species 
(not aureus). Blood culture repeated after 48 hours was 
positive for carbapenem-sensitive Klebsiella pneumoniae. 
The baby was moved to the isolation room. On the 24th 
DOL, the baby developed severe thrombocytopenia, with 
a platelet count of 22 × 103 cells/mm3, managed with the 
transfusion of 10 ml/kg platelet units [17].
On the 25th DOL, an episode of generalized tonic-
clonic fit occurred for which single-dose diazepam and a 
loading dose of phenobarbitone were given initially and 
then continued with maintenance doses of phenobarbi-
tone. Due to significant metabolic acidosis and desatu-
ration, the baby was re-intubated. After ID consult, 
meropenem was continued in meningitic doses and van-
comycin was discontinued. SIMV and a central line were 
placed. TPN was started with nothing per oral status.
Blood gases were monitored, and the baby was extu-
bated after 4 days and switched to CPAP. Phenobarbitone 
was discontinued after 6 days of therapy, and the baby 
was seizure-free through the remainder of the hospi-
tal stay. All repeat blood cultures were negative for any 
growth including CSF culture. The ID team was on board 
and decided to continue meropenem for a total of 14 days 
post-negative culture in septic doses of 20  mg/kg, and 
vancomycin was discontinued after 6 days. All repeated 
blood cultures obtained on the 27th and 30th DOL con-
firmed no pathogenic growth.
On the 33rd DOL, the CBC report showed WBC of 
8.7  ×  103  cells/mm3, ANC of 4576  cells/mm3, plate-
lets of 78 ×  103  cells/mm3, and hemoglobin of 10.8  g/
dl. On the 36th DOL, the CBC report showed WBC of 
5.1 ×  103 cells/mm3, ANC of 2917  cells/mm3, platelets 
of 29 ×  103 cells/mm3, and hemoglobin of 9.2 g/dl. The 
baby was managed for thrombocytopenia with platelet 
transfusion.
On the 37th DOL, hemoglobin dropped to 8.3  g/
dl in the evening, and platelet count improved to 
63 × 103 cells/mm3, WBC was 4.8 × 103 cells/mm3, and 
ANC was 1285 cells/mm3. On the 39th DOL, a marked 
reduction was observed in ANC to 816 cells/mm3, plate-
lets of 38 ×  103  cells/mm3, and hemoglobin of 8.3  g/dl, 
and the baby received blood transfusion to manage it. For 
constant issues, a hematological consult was taken and a 
decision was made to manage the baby symptomatically 
with 10 ml/kg platelet units at a platelet count < 50 [17] 
and 15 ml/kg packed cell transfusion at hemoglobin < 10 
g/dl [18].
On the 40th DOL, meropenem was discontinued 14 
days after negative culture (total of 19 days of mero-
penem therapy). On the same day the platelet count 
was 34 ×  103  cells/mm3, ANC was 818  cells/mm3, and 
hemoglobin was 10.2  g/dl, and the baby was transfused 
to manage these issues. After discontinuation of mero-
penem, the baby was continuously monitored for hema-
tological changes, and low counts persisted for 3 days. 
Improved ANC of > 1500 cells/mm3 was reported on the 
fourth day, and platelet count of > 150 × 103 cells/mm3 
was reported for the first time on the sixth day of mero-
penem discontinuation, but hemoglobin was still low 
(Fig 1). CPAP was tapered gradually to nasal prongs. The 
peripherally inserted central catheter was removed, and 
orogastric (OG) tube feeding was commenced. The baby 
was discharged on the 48th DOL on iron supplements 
with follow-up monitoring of CBC. Hemoglobin level of 
11.2 g/dl was found  on the 59th DOL.
Discussion
Drug-induced pancytopenia is a rare hematological 
problem in neonatal clinical practices, evaluated based 
on a complete underlying pathological history, physical 
examination, and vigilant interpretation of biochemical, 
radiological, histopathological, and hematological find-
ings [19]. Concerns have been raised about hematological 
adverse effects of several beta-lactamase inhibitors [8]. 
This neonatal case documents meropenem-induced pan-
cytopenia and emphasizes cautious laboratory monitor-
ing for patients receiving meropenem therapy.
Sepsis is another known etiology of pancytopenia. 
Although the neonate in the present case had a blood 
culture positive for K. pneumoniae, the results of all 
repeated blood cultures were negative, showing the 
resolution of sepsis. Van Tuyl et al. [20] also reported a 
case of a neonate receiving meropenem in meningitic 
doses of 40  mg/kg/day to treat meropenem-susceptible 
Enterobacter cloacae in blood culture. The baby devel-
oped meropenem-induced neutropenia on the 13th day 
of therapy, with ANC of 288 cells/mm3. The decision 
was made to discontinue meropenem on the 19th day 
of therapy instead of the initially planned 21 days. In the 
present case, the baby continued to receive meropenem 
treatment and was managed for hematological problems 
based on institutional guidelines and culture sensitivity. 
Initially, hematological changes were not considered as 
directly meropenem-induced.
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Recently published reports also support the notion 
of carbapenem-induced hematological disorders. A 
case report by Estella and colleagues [21] described 
meropenem-induced pancytopenia in a 3-year-old 
patient at 100 mg/kg given every 8 hours to manage the 
regrowth of meropenem-sensitive Morganella morga-
nii in CSF cultures. Huang et al. [6] reported a case of 
meropenem-induced immune thrombocytopenia in a 
59-year-old patient, by detecting meropenem-depend-
ent platelet antibodies and platelet count recovery after 
discontinuation of meropenem. Oka et al. [5] reported 
the development of severe anemia with clinical signs in 
a 76-year-old female patient, who received 2 g merope-
nem per day. On further investigation, they found  that 
a direct antiglobulin test (DAT) was positive for immu-
noglobulin G (IgG) and C3d, and reported the presence 
of meropenem-dependent antibodies in the patient’s 
serum [5].
The absence of drug-dependent antibody testing and 
bone marrow aspiration prevent us from drawing a firm 
conclusion regarding the mechanism of meropenem-
induced pancytopenia in the present case. However, the 
hematological findings with the progressive develop-
ment of thrombocytopenia, anemia, and then neutro-
penia suggest a possible mechanism of suppression of 
granulopoiesis or antibody-mediated destruction, as 
reported in recent studies [5, 6].
During hospitalization, the neonate received other 
medications, which have been reported to exert hemato-
logical effects. The baby initially received ampicillin, gen-
tamicin, and fluconazole, and then received meropenem, 
colistin, vancomycin, and phenobarbital. However, severe 
thrombocytopenia developed on the sixth day of the first 
course of meropenem therapy, when the baby was also 
on colistin and fluconazole. This issue was resolved when 
meropenem was discontinued. During the second course 
of meropenem therapy, the baby again developed severe 
thrombocytopenia on the third day, while also receiving 
vancomycin, fluconazole, and phenobarbital. Phenobar-
bital-induced hematological abnormalities are reported 
in animal and adult studies [22, 23], and therefore it was 
discontinued on the sixth day. No seizures were observed 
but counts did not improve. However, the baby devel-
oped severe anemia and neutropenia while receiving 
fluconazole and meropenem only. After meropenem dis-
continuation, severe anemia and neutropenia showed a 
resolving trend for 3  days. Severe neutropenia resolved 
on the fourth day, and hemoglobin was reported at > 10 
g/dl without transfusion on the seventh day of mero-





Fig. 1. Hematological changes and timing of medication during hospitalization
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continued from the beginning until the 56th DOL, which 
further confirms the association of meropenem-induced 
hematological changes in this baby. It was also confirmed 
that the baby did not experience any additional infection 
even  though she was not discharged on any antibiotic, 
which correlates with the fast recovery of blood counts 
after meropenem discontinuation.
Conclusions
In the present neonatal case, the gradual onset of hema-
tological irregularities correlates with the commence-
ment of meropenem therapy, and our observations 
are also verified by previously published evidence. The 
follow-up CBC count further established the resolution 
of pancytopenia after discontinuation of meropenem. 
Neonatal pancytopenia may lead to serious health com-
plications; therefore, clinicians and pharmacists need to 
vigilantly monitor CBC counts in this vulnerable popu-
lation, even when administering meropenem in septic 
doses for the recommended duration.
Patient perspective
From the perspective of the patient’s father, it was a rare 
case to have such kind of adverse events in a neonate 
with the normal treatment regimen. He was shared about 
all the events and he admired the team for the timely and 
effectively managing the issues and finally 100% recovery 
on the follow-ups.
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